세계의 암 줄기세포 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Cancer Stem Cell Market is presumed to reach the market size of nearly USD 5.35 Billion by 2032 from USD 1.86 Billion in 2023 with a CAGR of 12.43% under the study period 2024-2032.

Cancer stem cells are a small subset of cells within tumors capable of self-renewal and differentiation into various cell types found in the original tumor. They possess characteristics similar to normal stem cells, such as initiating and sustaining tumor growth, resisting conventional cancer therapies, and potentially metastasizing to other parts of the body. Identifying and targeting these cells is crucial in cancer treatment strategies, as their presence often correlates with tumor recurrence and treatment resistance. Understanding their biology and interactions within the tumor microenvironment is essential for developing effective therapies to eradicate cancer at its root.

MARKET DYNAMICS

The cancer stem cells (CSCs) field presents a promising avenue for advancing cancer treatment strategies. Market drivers for CSC research and therapies include the growing understanding of CSCs' role in cancer recurrence and resistance to traditional therapies. As researchers delve deeper into the molecular & genetic characteristics of CSCs, they increasingly recognize their potential as targets for more effective treatments that can specifically eradicate the root cause of tumor formation and metastasis. Moreover, the market opportunities in cancer stem cell research are expanding with advancements in technology and the development of novel therapeutics. Pharmaceutical companies & biotech firms are investing heavily in CSC-targeted drug discovery and development, aiming to capitalize on the potential benefits of targeting cancer stem cells in cancer therapy. The rising prevalence of cancer worldwide further underscores the urgent need for innovative treatment approaches that can improve patient outcomes and survival rates. Furthermore, collaborations between academia, research institutes, and industry players facilitate translating basic CSC research into clinical applications. However, the development of effective targeted therapies resistant to relapse, regulatory hurdles, and significantly increasing cost of therapy will likely hamper market growth during the forecast period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cancer Stem Cell. The growth and trends of Cancer Stem Cell industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cancer Stem Cell market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Mode of Action

• Targeted Cancerous Stem Cells (CSCs)
• (

By Anti-CSC Therapeutics (Pathway Inhibitors (WNT Signaling Pathway, Hedgehog Signaling Pathway, Notch Signaling Pathway, Others), Surface Marker-based, Immuno-evasion & Targeting Tumor Microenvironment, Nanoparticle-based Therapies, Others), Products (Cell-Culturing Cell-Separation Cell Analysis Molecular Analysis Others)

• Stem Cell-based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant)

By Cancer Forms

• Breast cancer
• Blood cancer
• Lung cancer
• Brain cancer
• Colorectal cancer
• Pancreatic cancer
• Bladder cancer
• Liver cancer
• Others cancer

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Stem Cell market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Stem Cell market include Thermo Fisher Scientific Inc., AbbVie Inc., Merck KGaA, Bionomics, Lonza, Stemline Therapeutics Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics Inc., OncoMed Pharmaceuticals Inc., Fujifilm Irvine Scientific, Stemcell Technologies., Sino Biological Inc., Lineage Cell Therapeutics Inc., . This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CANCER STEM CELL - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Mode of Action
  • 3.7.2 Market Attractiveness Analysis By Anti-CSC Therapeutics (Pathway Inhibitors (WNT Signaling Pathway, Hedgehog Signaling Pathway, Notch Signaling Pathway, Others), Surface Marker-based, Immuno-evasion & Targeting Tumor Microenvironment, Nanoparticle-based Therapies, Others), Products (Cell-Culturing Cell-Separation Cell Analysis Molecular Analysis Others)
  • 3.7.3 Market Attractiveness Analysis By Cancer Forms
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER STEM CELL MARKET ANALYSIS BY MODE OF ACTION

• 5.1. Overview By Mode of Action
• 5.2. Historical and Forecast Data Analysis By Mode of Action
• 5.3. Targeted Cancerous Stem Cells (CSCs) Historic and Forecast Sales By Regions
• 5.4. ( Historic and Forecast Sales By Regions

6. GLOBAL CANCER STEM CELL MARKET ANALYSIS BY ANTI-CSC THERAPEUTICS (PATHWAY INHIBITORS (WNT SIGNALING PATHWAY, HEDGEHOG SIGNALING PATHWAY, NOTCH SIGNALING PATHWAY, OTHERS), SURFACE MARKER-BASED, IMMUNO-EVASION & TARGETING TUMOR MICROENVIRONMENT, NANOPARTICLE-BASED THERAPIES, OTHERS), PRODUCTS (CELL-CULTURING CELL-SEPARATION CELL ANALYSIS MOLECULAR ANALYSIS OTHERS)

• 6.1. Overview By Anti-CSC Therapeutics (Pathway Inhibitors (WNT Signaling Pathway, Hedgehog Signaling Pathway, Notch Signaling Pathway, Others), Surface Marker-based, Immuno-evasion & Targeting Tumor Microenvironment, Nanoparticle-based Therapies, Others), Products (Cell-Culturing Cell-Separation Cell Analysis Molecular Analysis Others)
• 6.2. Historical and Forecast Data Analysis By Anti-CSC Therapeutics (Pathway Inhibitors (WNT Signaling Pathway, Hedgehog Signaling Pathway, Notch Signaling Pathway, Others), Surface Marker-based, Immuno-evasion & Targeting Tumor Microenvironment, Nanoparticle-based Therapies, Others), Products (Cell-Culturing Cell-Separation Cell Analysis Molecular Analysis Others)
• 6.3. Stem Cell-based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant) Historic and Forecast Sales By Regions

7. GLOBAL CANCER STEM CELL MARKET ANALYSIS BY CANCER FORMS

• 7.1. Overview By Cancer Forms
• 7.2. Historical and Forecast Data Analysis By Cancer Forms
• 7.3. Breast cancer Historic and Forecast Sales By Regions
• 7.4. Blood cancer Historic and Forecast Sales By Regions
• 7.5. Lung cancer Historic and Forecast Sales By Regions
• 7.6. Brain cancer Historic and Forecast Sales By Regions
• 7.7. Colorectal cancer Historic and Forecast Sales By Regions
• 7.8. Pancreatic cancer Historic and Forecast Sales By Regions
• 7.9. Bladder cancer Historic and Forecast Sales By Regions
• 7.10. Liver cancer Historic and Forecast Sales By Regions
• 7.11. Others cancer Historic and Forecast Sales By Regions

8. GLOBAL CANCER STEM CELL MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER STEM CELL COMPANIES

• 9.1. Cancer Stem Cell Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF CANCER STEM CELL INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Thermo Fisher Scientific Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. AbbVie Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Merck KGaA
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Bionomics
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Lonza
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Stemline Therapeutics Inc.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Miltenyi Biotec
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. PromoCell GmbH
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. MacroGenics Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. OncoMed Pharmaceuticals Inc.
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Fujifilm Irvine Scientific
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Stemcell Technologies.
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Sino Biological Inc.
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Lineage Cell Therapeutics Inc.
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17.
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies